The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Role of CD47 in Hematological Malignancies
Open accessAbstract
CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending a potent “don’t eat me” signal to prevent phagocytosis. A growing body of evidence demonstrates that CD47 is overexpressed in various hematological malignancies and its interaction with SIRPα on the phagocytic cells prevents phagocytosis of cancer cells. Additionally, it is expressed by different cell types in the tumor microenvironment and is required for establishing tumor metastasis. Overexpression of CD47 is thus often associated with poor clinical outcomes. CD47 has emerged as a potential therapeutic target and is being investigated in various preclinical studies as well as clinical trials to prove its safety and efficacy in treating hematological neoplasms. This review focuses on different therapeutic mechanisms to target CD47, either alone or in combination with other cell surface markers, and its pivotal role in impairing tumor growth and metastatic spread of various types of hematological malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Extracellular Matrix: Functions in the Nervous System
Barros, C. S., Franco, S. J., & Muller, U. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005108 · Cited by 506
Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47
Kaur, S., Martin-Manso, G., Pendrak, M. L., Garfield, S. H., Isenberg, J. S., & Roberts, D. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172304 · Cited by 235
SUZUKI, S., YOKOBORI, T., TANAKA, N., SAKAI, M., SANO, A., INOSE, T., SOHDA, M., NAKAJIMA, M., MIYAZAKI, T., KATO, H., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1831 · Cited by 100 · cited 1×
“into liposome-protamine-hyaluronic acid nanoparticles could regulate CD47 expression levels, and results from animal models of solid tumors suggested that they could represent potential cancer strategies [72, 73].”
BackgroundTremblay-LeMay, R., Rastgoo, N., & Chang, H. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0589-1 · Cited by 69
Self-citationDavis, R. M., Campbell, J. L., Burkitt, S., Qiu, Z., Kang, S., Mehraein, M., Miyasato, D., Salinas, H., Liu, J. T. C., & Zavaleta, C. (2018) · Nanomaterials · doi:10.3390/nano8110953 · Cited by 60 · cited 1×
“combined anti-CD47 antibodies with nanoparticles to target ovarian cancer cells [91].”
Background
Cited by
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
“CD47 is a transmembrane protein expressed in all types of cells, serves as a self‐marker and interacts with signal regulatory protein α (SIRPα) to inhibit phagocytosis by immune cells [252].”
BackgroundThe Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Metadata
- Authors
- Eladl, E., Tremblay-LeMay, R., Rastgoo, N., Musani, R., Chen, W., Liu, A., & Chang, H.
- Venue
- Journal of Hematology & Oncology
- Published
- 2020-07-16
- Volume
- 13
- Issue
- 1
- Pages
- 96-96
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W3042954004
- Cited by
- 160
- References
- 7
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of CD47 in Hematological Malignancies. https://app.cochat.ai/papers/10.1186/s13045-020-00930-1
- The paper
- Eladl, E., Tremblay-LeMay, R., Rastgoo, N., Musani, R., Chen, W., Liu, A., & Chang, H. (2020). Role of CD47 in Hematological Malignancies. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-020-00930-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.